InvestSMART

Bioxyne Limited (ASX: BXN) - Announcements

Current share price for BXN : $0.930 0.01 (1.06%)+

ASX company news and announcements for Bioxyne Limited (BXN) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Bioxyne Limited (BXN) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Bioxyne Limited (BXN), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Bioxyne Limited (BXN)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$214 Appendix 3H 3 Jul 2026 12:27PM $0.925 $0.930 risen by 0.54%
$214 Appendix 2A 3 Jul 2026 10:19AM $0.910 $0.930 risen by 2.20%
$214 Change of Name - BLS Pharmaceuticals Limited 29 Jun 2026 10:08AM $0.940 $0.930 fallen by 1.06%
$214 Application for quotation of securities - BXN 19 Jun 2026 5:31PM $0.105 $0.930 risen by 785.71%
$214 Results of Meeting 19 Jun 2026 3:42PM $0.110 $0.930 risen by 745.45%
$214 Bioxyne General Meeting 19.6.2026 18 Jun 2026 3:07PM $0.098 $0.930 risen by 848.98%
$214 Initial Director's Interest Notice 5 Jun 2026 9:31AM $0.087 $0.930 risen by 968.97%
$214 New Independent Director to Strengthen Board 3 Jun 2026 11:37AM $0.075 $0.930 risen by 1,140%
$214 Investor Presentation - Coffee Microcaps Webinar 1 Jun 2026 1:01PM $0.080 $0.930 risen by 1,062.50%
$214 Application for quotation of securities - BXN 26 May 2026 6:17PM $0.080 $0.930 risen by 1,062.50%
$214 Consolidation/Split - BXN 21 May 2026 5:39PM $0.074 $0.930 risen by 1,156.76%
$214 Letter to Shareholders re General Meeting Notice 21 May 2026 5:38PM $0.074 $0.930 risen by 1,156.76%
$214 Notice of General Meeting/Proxy Form 21 May 2026 5:38PM $0.074 $0.930 risen by 1,156.76%
$214 Application for quotation of securities - BXN 20 May 2026 7:15PM $0.076 $0.930 risen by 1,123.68%
$214 Change of Director's Interest Notice 15 May 2026 8:25AM $0.084 $0.930 risen by 1,007.14%
$214 Secures $50m Exclusive German Supply Agreement with ADREX 12 May 2026 8:22AM $0.072 $0.930 risen by 1,191.67%
$214 Expands LATAM Footprint First Supply Agreement Costa Rica 11 May 2026 8:24AM $0.070 $0.930 risen by 1,228.57%
$214 Quarterly Activities/Appendix 4C Cash Flow Report 21 Apr 2026 8:33AM $0.077 $0.930 risen by 1,107.79%
$214 Application for quotation of securities - BXN 14 Apr 2026 4:07PM $0.068 $0.930 risen by 1,267.65%
$214 Manufacturing Agreement Aurora Supplementary Information 1 Apr 2026 9:48AM $0.063 $0.930 risen by 1,376.19%
$214 Bioxyne Signs Manufacturing Agreement with Aurora Cannabis 1 Apr 2026 8:44AM $0.063 $0.930 risen by 1,376.19%
$214 Bioxyne - NWR Virtual Healthcare Conference Presentation 25 Mar 2026 8:52AM $0.047 $0.930 risen by 1,878.72%
$214 BXN to Present at NWR Virtual Conference today 9.30AM AEDT 25 Mar 2026 8:39AM $0.047 $0.930 risen by 1,878.72%
$214 Change of Director's Interest Notice 23 Mar 2026 8:18AM $0.051 $0.930 risen by 1,723.53%
$214 Cleansing 20 Mar 2026 7:01PM $0.051 $0.930 risen by 1,723.53%

1 - 25 of 457 results

Page 1 of 19

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.